AKBA - Company ID 0001517022
Akebia Therapeutics, Inc. trades as AKBA. In its fiscal 2025 annual report the company posted revenue of $236.20M, up 47.5% from the prior year and net income of -$5.30M. This page tracks Akebia Therapeutics, Inc. through 868 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Akebia Therapeutics, Inc.'s revenue grew from $1.53M to $236.20M, a compound annual growth rate of 75.0%. Net profit margin expanded from -8843.5% to -2.2% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
| PRE 14A | - | 2026-04-15 |
| Insider trade | 4 | 2026-04-03 |
The largest companies sharing Akebia Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Akebia Therapeutics, Inc. reported revenue of $236.20M for fiscal year 2025, an increase of 47.5% year over year.
In its latest fiscal year Akebia Therapeutics, Inc. reported a net loss of $5.30M.